Product Description
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, _-Catenin, and TRK pathways (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33409897/)
Mechanisms of Action: AURKA Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TAS-119-102 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2019-08-01 |
2020-02-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| TO-TAS-119-101 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2018-07-01 |
2020-02-22 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |